Tirzepatide and fatty liver disease linked to metabolism in people with obesity: a real-world multicenter study

Tirzepatide treatment may influence hepatic steatosis in patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

• MASLD is the most common chronic liver disease globally, linked to obesity and insulin resistance.
• Tirzepatide is associated with significant weight loss and improved metabolic control.
• Real-world evidence regarding the effects of tirzepatide on liver fat accumulation is currently limited.
• The study aims to evaluate how tirzepatide affects liver health in individuals with obesity and MASLD.
• Identifying clinical predictors of tirzepatide's impact on the liver is a key objective of the research.

Simplified